Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by ANALIAS00on Sep 08, 2017 12:18pm
135 Views
Post# 26672255

RE:RE:How will Ibalizumab be used?

RE:RE:How will Ibalizumab be used?Of course I am not a seller at this time.  Approval is comming, TH invested in a big marketting team and hopefully a good marketting strategy.  They had plenty of time to get ready for Ibalizumab's launch and this was part of their strategy: Be ready at day 1. Taimed invested in building their own drug manufacturing facilities, TH is now a player to consider as a distributor so they may acquire other product to distribute, TH may also be a target to be acquired, first sales number may surprise us, etc    

There are very low possible downside.  Kim vs Trump (I cant believe we have such men as world leaders), FDA delays, sales not as good as expected, bad TH decisions, etc

So I hope, yes I hope.  I hope the same scenario repeats itself again.  Same as when the stock price was at $2.00 and you guys with all your research, input, analysis were seing what  analysts and other investors refuse to see (or to believe or to conclude),  a stock at $7.37 that would worth a lot more in a year or two from now.   :o)

I may not have your optimisim, but I am optimist enought to wait for a higher SP before thinking of selling some shares.   I hope, yes I hope again, that I can say in a mid future, that AGAIN, those guys on this board were never optimistic, they were just able to put the facts and numbers togeters and wisely conclude that investing in TH was the right thing to do for any investors able to realise the potential of the situation TH put themself in.
Bullboard Posts